Universität zu Köln

Schlachtenberger, Georg ORCID: 0000-0001-7118-8432, Doerr, Fabian, Menghesha, Hruy, Heldwein, Matthias B., Lauinger, Patrick ORCID: 0000-0002-9338-639X, Wolber, Philipp, Klussmann, Jens Peter, Wahlers, Thorsten and Hekmat, Khosro (2022). Pulmonary metastasectomy for metastatic head and neck cancer prolongs survival significantly compared to non-surgical therapy. Eur. J. Cardio-Thorac. Surg., 62 (2). CARY: OXFORD UNIV PRESS INC. ISSN 1873-734X

Full text not available from this repository.

Abstract

OBJECTIVES Pulmonary metastasectomy (PM) is an established procedure for selected patients with metastatic head and neck cancer (HNC). Non-surgical therapy in the form of chemo- and immunotherapy and checkpoint inhibitors and radiation therapy are also treatment options. There are no randomized controlled trials comparing PM with non-surgical therapy. Here, we retrospectively compare the long-term survival of patients, undergoing PM with patients receiving non-surgical therapy. METHODS All HNC patients with pulmonary metastases were included, if the primary HNC was treated curatively and distant metastases, apart from the lungs were excluded. The pulmonary metastases were confirmed by biopsy as metastases of the HNC primary tumour in the non-surgical therapy group. To further clarify that PM prolonged survival, a propensity score-matched analysis was performed. RESULTS Between January 2010 and December 2020, 62 HNC patients with isolated pulmonary metastases were included in our analysis. Thirty-three underwent PM and 29 received non-surgical therapy. Histology, tumour stage and localization of the primary HNC did not differ between groups. The number of metastases, age and ASA classification did also not differ between the groups. Patients undergoing PM showed significantly better 1- (n = 31; 93.5% vs n = 19; 65.5%; P = 0.006), 3- (n = 17; 72.2% vs n = 9; 30.4%; P = 0.004) and 5-year (n = 10; 53.4% vs n = 4; 20.0%; P = 0.001) survival rates, compared to patients receiving non-surgical therapy. CONCLUSIONS Patients with pulmonary metastatic HNC undergoing PM had a significantly better overall survival compared to patients receiving non-surgical therapy. Therefore, selected patients should undergo PM to improve survival.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Schlachtenberger, Georg UNSPECIFIED orcid.org/0000-0001-7118-8432 UNSPECIFIED Doerr, Fabian UNSPECIFIED UNSPECIFIED UNSPECIFIED Menghesha, Hruy UNSPECIFIED UNSPECIFIED UNSPECIFIED Heldwein, Matthias B. UNSPECIFIED UNSPECIFIED UNSPECIFIED Lauinger, Patrick UNSPECIFIED orcid.org/0000-0002-9338-639X UNSPECIFIED Wolber, Philipp UNSPECIFIED UNSPECIFIED UNSPECIFIED Klussmann, Jens Peter UNSPECIFIED UNSPECIFIED UNSPECIFIED Wahlers, Thorsten UNSPECIFIED UNSPECIFIED UNSPECIFIED Hekmat, Khosro UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-663015
DOI:	10.1093/ejcts/ezac098
Journal or Publication Title:	Eur. J. Cardio-Thorac. Surg.
Volume:	62
Number:	2
Date:	2022
Publisher:	OXFORD UNIV PRESS INC
Place of Publication:	CARY
ISSN:	1873-734X
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language SQUAMOUS-CELL CARCINOMA; ADENOID CYSTIC CARCINOMA; SURGICAL RESECTION; RECURRENT; NIVOLUMAB; CETUXIMAB Multiple languages Cardiac & Cardiovascular Systems; Respiratory System; Surgery Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/66301